Brielle Benyon

A telephone and web-based weight loss intervention was successful in helping patients with breast cancer who were overweight or obese lose weight—which can ultimately lead to improved outcomes.

Fewer Americans are aware of the fact that the human papillomavirus can cause certain types of cancer, and vaccination rates against the virus are lagging, according to recent research presented at the AACR Annual Meeting 2023.

Sequencing treatment with Lutetium 177 PSMA-617 after radium-223 was safe and well tolerated and demonstrated similar overall survival in patients with metastatic castration-resistant prostate cancer regardless of whether they received 177Lu-PSMA-617 within 6 months or after 6 months of completing radium-223.

The use of frontline ibrutinib was associated with a longer time to next treatment compared with acalabrutinib in patients with chronic lymphocytic leukemia.

Zanubrutinib sustained high response rates and led to durable disease control with low incidence of hypertension and atrial fibrillation in patients with relapsed/refractory marginal zone lymphoma, according to findings from the final analysis of the phase 2 MAGNOLIA trial.

Lenvatinib plus pembrolizumab maintained clinically meaningful benefits in outcomes vs physician’s choice of therapy for patients with advanced endometrial cancer who received prior platinum-based chemotherapy.

Tiragolumab combined with atezolizumab plus carboplatin and etoposide demonstrated no additional survival benefits compared with atezolizumab plus chemotherapy alone in patients with treatment-naïve, extensive-stage small cell lung cancer.

Patients with advanced renal cell carcinoma who received lenvatinib plus pembrolizumab experienced a longer time to progression on next line of therapy compared with those who received sunitinib.

Daratumumab plus induction/consolidation lenalidomide, bortezomib, and dexamethasone elicited higher minimal residual disease-negativity rates vs the RVd combination alone in patients with transplant-eligible newly diagnosed multiple myeloma, including those in high-risk subgroups.

Treatment with pacritinib demonstrated a comparable safety profile to best available therapies for the treatment of patients with myelofibrosis.

For Dawn Hershman, MD, MS, research and medicine are art forms that she uses to uplift and inspire every day.

Follow-up from the TIVO-3 trial showed that patients with pretreated relapsed/refractory renal cell carcinoma who received tivozanib were 5 times more likely to experience long-term progression-free survival compared with sorafenib.

Frontline tivozanib was noninferior to other tyrosine kinase inhibitors for the treatment of patients with metastatic renal cell carcinoma in a real-world setting.

Prognostic awareness was associated with higher rates of psychosocial distress and symptom burden, and lower quality of life in patients with multiple myeloma.

Naratuximab emtansine plus rituximab had promising response rates while also improving patient well-being when used to treat diffuse relapsed/refractory large B-cell lymphoma and other non-Hodgkin B-cell lymphomas.

Depression and anxiety can play a significant role in how patients with cancer view cancer clinical trials, ultimately leading to low enrollment

Vic-trastuzumab duocarmazine yielded an improved progression-free survival over standard physician’s choice chemotherapy in patients with pretreated HER2-positive locally advanced or metastatic breast cancer.

Cabozantinib as a second-line treatment showed improved overall survival outcomes compared with second-line axitinib in patients with advanced renal cell carcinoma.

The clinical response to sotorasib could vary in patients with KRAS G12C–mutated non–small cell lung cancer depending on their co-mutational status.

With more oral cancer therapies available, the importance of medication adherence and education must be recognized.

Neurologic adverse effect associated with CAR T-cell therapies like ciltacabtagene autoleucel can be managed without long-term lasting effects, as long as they are caught and treated promptly in patients with relapsed/refractory multiple myeloma.

The BCMA-targeting humanized bispecific monoclonal antibody elranatamab elicited high response rates when subcutaneously delivered at higher doses in patients with relapsed/refractory multiple myeloma.

Larotrectinib has demonstrated efficacious responses and disease control in patients with TRK fusion–positive central nervous system tumors.

The addition of nivolumab to either ipilimumab or chemotherapy resulted in improved survival outcomes vs chemotherapy alone in the frontline treatment of patients with unresectable advanced or metastatic esophageal squamous cell carcinoma.

February 11, 2021 - Eganelisib, a novel PI3K-y inhibitor, demonstrated higher responses rates with nivolumab in patients with metastatic urothelial carcinoma.

February 2, 2021 - Virtual prehabilitation could potentially improve physical activity level and exercise capacity in patients with lung cancer before they undergo surgery for their disease.

January 28, 2021- Patients with non-small cell lung cancer who experience immune-related adverse events may have better survival outcomes than those without.

January 15, 2021 - A novel artificial intelligence-based search tool made it easier for patients to find and understand cancer clinical trials, while also offering more clarity on how to enroll in them

Young Hope Rugo saved up her S&H Green Stamps to buy a children’s chemistry set from a Sears catalog. At the age of 8, Rugo knew she wanted to be a scientist.